By Todd Berry
At the height of the pandemic, economists and sociologists alike prophesied a second Roaring Twenties, during which people would emerge from their quarantine bubbles ready to throw money at restaurants, theaters, and anything else that promised socialization and distraction from memories of COVID-19. While society at large may not yet live up to the fantasies conjured in quarantine, the business of biotech mergers and acquisitions really does seem ripe for a resurgence.
Biotech M&A was slow in the first half of 2021, but that may be changing, with emerging trends indicating that a biotech M&A boom could be on the horizon. If your biotech is hoping to be acquired by a larger pharma company, it’s crucial that you start preparing now.